Beruflich Dokumente
Kultur Dokumente
Maulik P. Suthar
INTRODUCTION
Erythropoietin (EPO) is a 30,400-dalton glycoprotein that regulates red cell production. EPO acts primarily to rescue erythroid cells from apoptosis (programmed cell death) to increase their survival. Miyake et al. reported purification to homogeneity of human EPO. The kidney was proven to be the primary site of production of EPO. Loya et al. using hypoxic transgenic mice, reported a tubular epithelial cell site for EPO production.
Erythropoietin
Erythropoietin, or its alternative erythropoetin or EPO, is a glycoprotein hormone that controls erythropoiesis, or red blood cell production. It is a cytokine for erythrocyte (red blood cell) precursors in the bone marrow. Also called hematopoietin or hemopoietin, it is produced by the kidney, and is the hormone that regulates red blood cell production. It also has other known biological functions. For example, erythropoietin plays an important role in the brain's response to neuronal injury. EPO is also involved in the wound healing process. When exogenous EPO is used as a performance-enhancing drug, it is classified as an erythropoiesis-stimulating agent (ESA). Exogenous EPO can often be detected in blood, due to slight difference from the endogenous protein, for example in features of posttranslational modification.
Erythropoietin
Erythropoietin (EPO) is a glycoprotein hormone of 3438 kDa which stimulates proliferation and differentiation of erythroid precursor cells (CFU-E, BFU-E) to more mature erythrocytes. EPO is primarily produced in adult kidney and fetal liver cells. Cells responsive to EPO have been identified in adult bone marrow, fetal liver or adult spleen. In cultures of erythropoietic progenitor cells, EPO stimulates the proliferation and differentiation of these cells to more mature red blood cells. Erythropoietin (EPO) regulates the level of erythrocytes in response to the level of oxygen in the blood. When tissues meet hypoxic conditions, the EPO level in the blood increases, and the elevated EPO level triggers differentiation of progenitor cells in bone marrow and release of erythrocytes from bone marrow into the blood.
Erythropoietin - structure
Erythropoietin - structure
EPO Receptor
EPO Receptor
Erythropoietin mechanism
Erythropoietin mechanism
Anemia and erythropoietin synthesis. (A) The healthy kidney maintains the balance between erythrocyte production and erythrocyte loss. In anemia because of (B) iron deficiency or (C) hemolysis, the kidney senses a reduction in hemoglobin level and increases erythropoietin synthesis in an attempt to stimulate erythrocyte production. (D) In the diabetic kidney, sensing of hemoglobin level is uncoupled from erythropoietin synthesis
Erythropoietin mechanism
ERYTHROPOIETIN MARKET
Vintor
Emcure Pharma
2001
Epofer
Emcure(Shweiz)
2001
Wepox
Wockhardt
2001
Epotin
Zyrop
Zydus Biogen
Hemax
Hindustan Antibiotics
2000
Shanpoietin
Shantha Biotechnics
2005
Ceriton
Ranbaxy
2003
Intas Pharmaceuticals
2005
BIOCON
Epofit 2k Epofit 4k
Intas Pharmaceuticals
2005
US Erythropoetin market
Brand name Generic name Company Year of Launch Vial/tablet Price (USD)
Epogen/ Procrit
Epoetin alfa
Amgen, Inc.
1989
2,000 unit/ml 3,000 unit/ml 4,000 unit/ml 10,000 unit/ml (1 vial, 2ml) 10,000 unit/ml (10 vials, 1 ml) 40,000 unit/ml (10 vials, 1 ml) 20,000 unit/ml (10 ml)
Aranesp
Amgen, Inc.
2002
200 mcg/1 mL 300 mcg/1 mL 500 mcg/1 mL (Prepare in both Polysorbate Solution and albumin solution)
Bio-generic Molecule
Market Size
Market Size
Market Size
INR
USD
INR
USD
INR
USD
(Crores)
(Millions)
(Crores)
(Millions)
(Percent)
(Crores)
(Millions)
(Percent)
Erythropoietin (EPO)
35.2
7.26
283.2
58.39
68
412
84.95
21
ERYTHROPOIETIN PRODUCTION
Host cell
Transfection Transformation
Plasmid construction
Host cell
EPO Production
Up-stream Down-stream
BIOASSAY
Bioassay on the mouse for determination of the specific activity in vivo of EPO from human cell lines. Result: EPO from cell line HeLa S3 (Sample 1) HeLa S3 (Sample 2) Specific Activity U/mg 100,000 110,000
2009, Maulik P. Suthar
PATENTS
Sr. No Patents title US Patent No. Filling date Applicant Outcomes 1 Production of erythropoietin 5621080 06/06/1995 Lin Fu-Kuen. Genomic DNA, cDNA and manufactured DNA sequences coding for part or all of the sequences of amino acid residues of EPO or for analogs thereof are incorporated into autonomously replicating plasmid or viral vectors employed to transform or transfect suitable procaryotic or eucaryotic host cells such as bacteria, yeast or vertebrate cells in culture. DNA encoding modified, secretable erythropoietin proteins whose ability to regulate the growth and differentiation of red blood cell progenitors are different from the wildtype recombinant erythropoietin and to methods of modifying or altering the regulating activity of a secretable erythropoietin and using modified secretable erythropoietin proteins. The present invention provides aqueous pharmaceutical formulations of erythropoietin that are free of human serum blood products, stabilized with a quantity of an amino acid and a sorbitan mono-9-octadecenoate poly (oxy-1,2ethanediyl) derivative and also provides aqueous stable, preserved pharmaceutical formulations of erythropoietin that contain an antimicrobial quantity of cresol and a quantity of an amino acid. 2009, Maulik P. Suthar
6489293
03/06/2000
6696056
04/07/2000
Basant Sharma, Wing K. Cheung, Selima Begum, Els Vercammen, Jaya Natarajan, Marilyn Sanders.
SUMMARY
The past decade has been characterized by a growing awareness of the role of anemia with respect to impairment of cancer patients. Novel technology has recently been expanded by the recent improvements in upstream and downstream processing in commercial production of EPO. Now a day, erythropoietin market size in India is approximately 21 % that indicate faster EPO market growth. The erythropoietin therapy with maintaining normal Hb levels may improve treatment outcomes, including overall survival and disease-free survival in anemic cancer patients.
2009, Maulik P. Suthar
References
JUDITH B. SHERWOOD*, Continuous production of erythropoietin by an established human renal carcinoma cell line: Development of the cell line, Proc. Natl. Acad. Sci. USA, Vol. 83, pp. 165169, January 1986